CAR T-Cell Immunotherapy is a new type of cancer treatment. This emerging treatment represents one of the biggest breakthroughs since the introduction of chemotherapy. T cells is a type of white blood cell extracted from the patient’s blood by doctors, and added an artificial receptor to their surface. When infused into a patient, the cells get multiplied and stay in the body as “living drugs” and help in detecting and fighting cancer. CAR-T cell therapy is defined as a type of immunotherapy that teaches T cells to recognize and destroy cancer.
This report contains market size and forecasts of CAR T-Cell Immunotherapy in Global, including the following market information:
Global CAR T-Cell Immunotherapy Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global CAR T-Cell Immunotherapy market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Monotherapy Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of CAR T-Cell Immunotherapy include AbbVie, Celgene, Kite Pharma, Oxford BioMedica, Novartis, Gilead, Pfizer, Cellectis and Bellicum, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the CAR T-Cell Immunotherapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global CAR T-Cell Immunotherapy Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global CAR T-Cell Immunotherapy Market Segment Percentages, by Type, 2021 (%)
Monotherapy
Combination Therapy
Global CAR T-Cell Immunotherapy Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global CAR T-Cell Immunotherapy Market Segment Percentages, by Application, 2021 (%)
Hematologic Malignancies
Solid Malignancies
Global CAR T-Cell Immunotherapy Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global CAR T-Cell Immunotherapy Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies CAR T-Cell Immunotherapy revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies CAR T-Cell Immunotherapy revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
AbbVie
Celgene
Kite Pharma
Oxford BioMedica
Novartis
Gilead
Pfizer
Cellectis
Bellicum
Mustang Bio
CARsgen Therapeutics
Xyphos
Minerva Biotechnologies
Adaptimmune
Ziopharm Oncology
Aurora Biopharma
Creative Biolabs